INVESTMENTS

In 2019, we invested in the 26-acre multi-use campus known as Pegasus Park, and worked with partners at J.Small Investments and Montgomery Street Partners to transform the property into a hub for life sciences and one of the largest social impact campuses in the country.

We invested in a Flagship Pioneering fund focused on incubating and funding early-stage biotechnology companies. One of the portfolio companies of the fund is Moderna, thus we became an early investor in Moderna, which develops novel mRNA platforms and products such as their widely used vaccine for COVID-19.

Reata was incubated in 2002 at UT Southwestern Medical Center in Dallas to develop therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. In 2003, we invested in Reata, which was acquired by Biogen for $7.3 billion in 2023.

In 2022, we provided a loan to Rocky Mountain Institute to fund MiQ, a spin out non-profit created to monitor and reduce methane emissions in the oil and gas sector by establishing a certification standard for methane emissions throughout the natural gas value chain. The investment is ongoing and in its early stages.

In 2011, Lyda Hill launched a $200 million biotechnology venture fund, Remeditex Ventures. The fund invested in promising early-stage life science technologies spinning out of Texas medical institutions. The deal sizes ranged from $50,000 to $5,000,000 across biomedical, pharmaceuticals, diagnostics, and medical devices.